Skip to main content

Advertisement

Log in

Neurological adverse events associated with anti-tumor necrosis factor alpha treatment

  • Review
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Anti-tumor necrosis factor alpha (TNF-α) drugs have been successfully used for the treatment of rheumatic autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, ankylosing spondylitis (AS), juvenile chronic arthritis, and Crohn’s disease. However, they have been associated with different neurological disorders, including alterations of peripheral nerves, multiple sclerosis (MS), optic neuritis (ON) and acute transverse myelitis (ATM). This article reviews the most current aspect regarding neurological adverse events associated with anti-TNF-α drugs with emphasis on the possible explanations for this relation and the pathogenic mechanism of TNF-α in neurological disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58(Suppl. 1):I32–I39

    Article  CAS  PubMed  Google Scholar 

  2. Stubgen JP (2008) Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 37:282–292

    Article  Google Scholar 

  3. Cope A, Ettinger R, McDevitt H (1997) The role of TNF-α and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 148:307–312

    Article  CAS  PubMed  Google Scholar 

  4. Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The role of tumor necrosis factor and receptors in models of multi organ inflammation, rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. Ann Rheum Dis 58(suppl 1):32–39

    Article  Google Scholar 

  5. Robinson WH, Genovese MC, Moreland LW (2001) Demyelinating and neurologic events reported in association with tumor necrosis factor α antagonism. Arthritis Rheum 44:1977–1983

    Article  CAS  PubMed  Google Scholar 

  6. Hohlfeld R (1996) Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler 1:376–378

    CAS  PubMed  Google Scholar 

  7. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ (1995) Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377:348–351

    Article  CAS  PubMed  Google Scholar 

  8. Alldred A (2001) Etanercept in rheumatoid arthritis. Expert Opin Pharmacother 1:1137–1148

    Article  Google Scholar 

  9. Enbrel (etanercept) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 584–591

  10. Humira (adalimumab) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 466–471

  11. Remicade (infliximab) (2007) Current prescribing information. In: Physicians’ desk reference. Thompson, Montvale, pp 971–979

  12. Ramos-Casals M, Roberto-Perez-Alvarez, Diaz-Lagares C, Cuadrado MJ, Khamashta MA et al (2010) Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 9(3):188–193

    Article  CAS  PubMed  Google Scholar 

  13. Wetter DA, Davis MD (2009) Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 84(11):979–984

    Article  CAS  PubMed  Google Scholar 

  14. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E (2009) Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J 102(11):1133–1140

    PubMed  Google Scholar 

  15. Ghezzi P, Mennini T (2001) Tumor necrosis factor and motoneural degeneration: an open problem. Neuroimmunomodulation 9(4):178–182

    Article  CAS  PubMed  Google Scholar 

  16. Cope AP, Liblau RS, Yang XD, Congia M, Laudanna C, Schreiber RD (1997) Chronic tumor necrosis factor alter T cell responses by attenuating T cell receptor signaling. J Exp Med 185:1573–1584

    Article  CAS  PubMed  Google Scholar 

  17. Aggarwal BB, Samanta A, Feldmann M (2000) TNFα. In: Oppenheim JJaFM (ed) Cytokine Reference. Academic Press, London, pp 414–434

    Google Scholar 

  18. Idriss HT, Naismith J (2000) TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 50:184–195

    Article  CAS  PubMed  Google Scholar 

  19. MacEwan DJ (2002) TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14:477–492

    Article  CAS  PubMed  Google Scholar 

  20. McCoy MK, Tansey MG (2008) TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 5:45

    Article  PubMed  Google Scholar 

  21. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF et al (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells. Nature 385:729–733

    Article  CAS  PubMed  Google Scholar 

  22. Lieberman AP, Pitha PM, Shin HS, Shin ML (1989) Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 86:6348–6352

    Article  CAS  PubMed  Google Scholar 

  23. Morganti-Kossman MC, Lenzlinger PM, Hans V, Stahel P, Csuka E, Ammann E et al (1997) Production of cytokines following brain injury: beneficial and deleterious for the damaged tissue. Mol Psychiatry 2:133–136

    Article  CAS  PubMed  Google Scholar 

  24. Chung CY, Seo H, Sonntag KC, Brooks A, Lin L, Isacson O (2005) Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. Hum Mol Genet 14:1709–1725

    Article  CAS  PubMed  Google Scholar 

  25. Creange A, Lefaucheur JP, Authier FJ, Gherardi RK (1998) Cytokines and peripheral neuropathies. Rev Neurol 154:208–216

    CAS  PubMed  Google Scholar 

  26. Oka N, Akiguchi I, Kawasaki T, Mizutani K, Satoi H, Kimura J (1998) Tumor necrosis factor-alpha in peripheral nerve lesions. Acta Neuropathol 95:57–62

    Article  CAS  PubMed  Google Scholar 

  27. Grell M, Wajant H, Zimmermann G, Scheurich P (1998) The type 1 receptor (CD1 20a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci USA 95:570–575

    Article  CAS  PubMed  Google Scholar 

  28. Grell M (1995) Tumor necrosis factor (TNF) receptors in cellular signaling of soluble and membrane-expressed TNF. J Inflamm 47:8–17

    CAS  PubMed  Google Scholar 

  29. Balkwill F (2009) Tumor necrosis factor and cancer. Nat Rev Cancer 9(5):361–371

    Article  CAS  PubMed  Google Scholar 

  30. Ihnatko R, Kubes M (2007) TNF signaling: early events and phosphorylation. Gen Physiol Biophys 26(3):159–167

    CAS  PubMed  Google Scholar 

  31. Haas E, Grell M, Wajant H, Scheurich P (1999) Continuous autotropic signaling by membrane expressed tumor necrosis factor. J Biol Chem 274(25):18107–18112

    Article  CAS  PubMed  Google Scholar 

  32. Weiss T, Grell M, Hessabi B, Bourteele S, Müller G, Scheurich P et al (1997) Enhancement of TNF receptor p60-mediated cytotoxicity by TNF receptor p80: requirement of the TNF receptor-associated factor-2 binding site. J Immunol 158(5):2398–2404

    CAS  PubMed  Google Scholar 

  33. Holtmann MH, Neurath MF (2004) Differential TNF-signaling in chronic inflammatory disorders. Curr Mol Med 4(4):439–444

    Article  CAS  PubMed  Google Scholar 

  34. Pocsik E, Duda E, Wallach D (1995) Phosphorylation of the 26 kDa TNF precursor in monocytic cells and in transfected HeLa cells. J Inflamm 45:152–160

    CAS  PubMed  Google Scholar 

  35. Watts AD, Hunt NH, Wanigasekara Y, Bloomfield G, Wallach D, Roufogalis BD et al (1999) A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in ‘reverse signalling’. EMBO J 18:2119–2126

    Article  CAS  PubMed  Google Scholar 

  36. Kirchner S, Boldt S, Kolch W, Haffner S, Kazak S, Janosch P et al (2004) LPS resistance in monocytic cells caused by reverse signaling through transmembrane TNF (mTNF) is mediated by the MAPK/ERK pathway. J Leukoc Biol 75:324–331

    Article  CAS  PubMed  Google Scholar 

  37. Tansey MG, Wyss-Coray T (2008) Cytokines in CNS inflammation and disease. In: Lane TE, Carson M (eds) Central nervous system diseases and inflammation. Springer, Berlin

  38. Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnan CF (1990) Proliferation of astrocytes in vitro in response to cytokines. A primary role for tumor necrosis factor. J Immunol 144:129–135

    CAS  PubMed  Google Scholar 

  39. Merrill JE (1991) Effects of interleukin-1 and tumor necrosis factoralpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev Neurosci 13:130–137

    Article  CAS  PubMed  Google Scholar 

  40. Sedgwick JD, Riminton DS, Cyster JG, Korner H (2001) Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 21:110–113

    Article  Google Scholar 

  41. Leon LR (2002) Invited review: cytokine regulation of fever: studies using gene knockout mice. J Appl Physiol 92:2648–2655

    CAS  PubMed  Google Scholar 

  42. Beattie EC, Stellwagen D, Morishita W, Bresnahan JC, Ha BK, Von Zastrow M et al (2002) Control of synaptic strength by glial TNFalpha. Science 295:2282–2285

    Article  CAS  PubMed  Google Scholar 

  43. Pickering M, Cumiskey D, O’Connor JJ (2005) Actions of TNF-alpha on glutamatergic synaptic transmission in the central nervous system. Exp Physiol 90:663–670

    Article  CAS  PubMed  Google Scholar 

  44. Golan H, Levav T, Mendelsohn A, Huleihel M (2004) Involvement of tumor necrosis factor alpha in hippocampal development and function. Cereb Cortex 14:97–105

    Article  CAS  PubMed  Google Scholar 

  45. Zou JY, Crews FT (2005) TNF alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 1034:11–24

    Article  CAS  PubMed  Google Scholar 

  46. Choi DW (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623–634

    Article  CAS  PubMed  Google Scholar 

  47. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV (1996) TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4:387–396

    Article  CAS  PubMed  Google Scholar 

  48. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C et al (1999) Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 274:1156–1163

    Article  CAS  PubMed  Google Scholar 

  49. Goodman JC, Robertson CS, Grossman RG, Narayan RK (1990) Elevation of tumor necrosis factor in head injury. J Neuroimmunol 30:213–217

    Article  CAS  PubMed  Google Scholar 

  50. Hofman FM, Hinton DR, Johnson K, Merrill JE (1989) Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 170:607–612

    Article  CAS  PubMed  Google Scholar 

  51. Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472

    Article  CAS  PubMed  Google Scholar 

  52. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78:318–323

    Article  CAS  PubMed  Google Scholar 

  53. Maimone D, Gregory S, Arnason BGW, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32:67–74

    Article  CAS  PubMed  Google Scholar 

  54. Selmaj KW, Raine CS (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23:339–346

    Article  CAS  PubMed  Google Scholar 

  55. Cre′ange A, Be′lec L, Clair B, Raphael JC, Gherardi RK (1996) Circulating tumor necrosis factor (TNF)-α and soluble TNF-α receptors in patients with Guillain–Barre′ syndrome. J Neuroimmunol 68:95–99

    Article  Google Scholar 

  56. Misawa S, Kuwabara S, Mori M, Kawagushi N, Yoshiyama Y, Hattori T (2001) Serum levels of tumor necrosis factor-α in chronic inflammatory polyneuropathy. Neurology 56:666–669

    CAS  PubMed  Google Scholar 

  57. Sharief MK, McLean B, Thompson EJ (1993) Elevated serum levels of tumor necrosis factor-α in Guillain–Barre′ syndrome. Ann Neurol 33:591–596

    Article  CAS  PubMed  Google Scholar 

  58. Terenghi F, Allaria S, Nobile-Orazio E (2006) Circulating levels of cytokines and their modulation by intravenous immunoglobulin in multifocal motor neuropathy. J Peripher Nerv Syst 11:67–71

    Article  CAS  PubMed  Google Scholar 

  59. Zhu J, Mix E, Link H (1998) Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain–Barre′ syndrome. J Neuroimmunol 84:40–52

    Article  CAS  PubMed  Google Scholar 

  60. Said G, Hontebeyrie-Joskowicz M (1992) Nerve lesions induced by macrophage activation. Res Immunol 143:589–599

    Article  CAS  PubMed  Google Scholar 

  61. Stoll G, Jung S, Jander S, van der Meide P, Hartung HP (1993) Tumor necrosis factor-alpha in immune-mediated demyelination and Wallerian degeneration of the rat peripheral nervous system. J Neuroimmunol 45:175–182

    Article  CAS  PubMed  Google Scholar 

  62. Weishaupt A, Bruck W, Hartung T, Toyka KV, Gold R (2001) Schwann cell apoptosis in experimental autoimmune neuritis of the Lewis rat and the functional role of tumor necrosis factor-α. Neurosci Lett 306:77–80

    Article  CAS  PubMed  Google Scholar 

  63. Magnano MD, Robinson WH, Genovese MC (2004) Demyelination and inhibition of tumor necrosis factor (TNF). Clin Exp Rheumatol 22(suppl. 35):S134–S140

    CAS  PubMed  Google Scholar 

  64. Selmaj KW, Raine CS (1995) Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 45:S44–S49

    CAS  PubMed  Google Scholar 

  65. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM et al (1996) Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal antitumor necrosis factor antibody cA2. Neurology 47:1531–1534

    PubMed  Google Scholar 

  66. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465

    Google Scholar 

  67. Klinkert WE, Kojima K, Lesslauer W, Rinner W, Lassmann H, Wekerle H (1997) TNFa receptor fusion protein prevents experimental autoimmune encephalomyelitis and demyelination in Lewis rats: an overview. J Neuroimmunol 72:163–168

    Article  CAS  PubMed  Google Scholar 

  68. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H et al (2001) Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44(12):2862–2869

    Article  CAS  PubMed  Google Scholar 

  69. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN (2006) Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54(5):1429–1434

    Article  CAS  PubMed  Google Scholar 

  70. Simsek I, Erdem H, Pay S, Sobaci G, Dinc A (2007) Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 66(9):1255–1258

    Article  CAS  PubMed  Google Scholar 

  71. Lees CW, Ali AI, Thompson AI, Ho GT, Forsythe RO, Marquez L et al (2009) The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther 29(3):286–297

    Article  CAS  PubMed  Google Scholar 

  72. Bernatsky S, Renoux C, Suissa S. Demyelinating events in rheumatoid arthritis after drug exposures. Ann Rheum Dis published online 23 Jul 2009; doi:10.1136/ard.2009.111500

  73. Lozeron P, Denier C, Lacroix C, Adams D (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490–497

    Article  PubMed  Google Scholar 

  74. Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57(10):1885–1888

    CAS  PubMed  Google Scholar 

  75. Muteis-Olivas E, Pérez-García C, Roquer-González J, Maymo-Guarch J (2005) Esclerosis múltiple tras el tratamiento con anticuerpo anti-TNF-α. Med Clin (Barc) 125:756–759

    Google Scholar 

  76. Dubcenco E, Ottaway CA, Chen DL, Baker JP (2006) Neurological symptoms suggestive of demyelination in Crohn’s disease after infliximab therapy. Eur J Gastroenterol Hepatol 18(5):565–566

    Article  PubMed  Google Scholar 

  77. Enayati PJ, Papadakis KA (2005) Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol 39(4):303–306

    Article  PubMed  Google Scholar 

  78. Richez C, Blanco P, Lagueny A, Schaeverbeke T, Dehais J (2005) Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 64(8):1468–1470

    CAS  PubMed  Google Scholar 

  79. Richette P, Dieudé P, Damiano J, Lioté F, Orcel P, Bardin T (2004) Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. J Rheumatol 31(10):2079–2081

    PubMed  Google Scholar 

  80. Thomas CW Jr, Weinshenker BG, Sandborn WJ (2004) Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn’s disease. Inflamm Bowel Dis 10(1):28–31

    Article  PubMed  Google Scholar 

  81. Vadikolias K, Kouklakis G, Heliopoulos I, Argyropoulou P, Papanas N, Tzilonidou M et al (2007) Acute paraplegia after the initiation of anti-tumour necrosis factor-alpha therapy for Crohn’s disease. Eur J Gastroenterol Hepatol 19(2):159–162

    Article  CAS  PubMed  Google Scholar 

  82. Cay HF, Gungor HA, Sezer I, Kacar C, Balci N (2006) Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 31(6):645–648

    Article  CAS  PubMed  Google Scholar 

  83. Jarand J, Zochodne DW, Martin LO, Voll C (2006) Neurological complications of infliximab. J Rheumatol 33(5):1018–1020

    PubMed  Google Scholar 

  84. Tanno M, Nakamura I, Kobayashi S, Kurihara K, Ito K (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25(6):929–933

    Article  PubMed  Google Scholar 

  85. Winkelmann A, Patejdl R, Wagner S, Benecke R, Zettl UK (2008) Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 255(Suppl 6):109–114

    Article  PubMed  Google Scholar 

  86. Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T (2009) Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45(2):55–57

    Article  CAS  PubMed  Google Scholar 

  87. Freeman HJ, Flak B (2005) Demyelination-like syndrome in Crohn’s disease after infliximab therapy. Can J Gastroenterol 19(5):313–316

    PubMed  Google Scholar 

  88. Hooper DR, Tarnopolsky MA, Baker SK (2008) Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. Muscle Nerve 38(4):1318–1325

    Article  CAS  PubMed  Google Scholar 

  89. Tektonidou MG, Serelis J, Skopouli FN (2007) Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment. Clin Rheumatol 26(2):258–260

    Article  PubMed  Google Scholar 

  90. Sukal SA, Nadiminti L, Granstein RD (2006) Etanercept and demyelinating disease in a patient with psoriasis. J Am Acad Dermatol 54(1):160–164

    Article  PubMed  Google Scholar 

  91. Berthelot CN, George SJ, Hsu S (2005) Distal lower extremity paresthesia and foot drop developing during adalimumab therapy. J Am Acad Dermatol 53(5 Suppl 1):S260–S262

    Article  PubMed  Google Scholar 

  92. Cocito D, Bergamasco B, Tavella A, Poglio F, Paolasso I, Costa PC et al (2005) Multifocal motor neuropathy during treatment with infliximab. J Peripher Nerv Syst 10(4):386–387

    Article  PubMed  Google Scholar 

  93. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, Gonzalez C, Figueroa M (2005) Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. Rheumatology (Oxford) 44(1):132–133

    Article  CAS  Google Scholar 

  94. Singer OC, Otto B, Steinmetz H, Ziemann U (2004) Acute neuropathy with multiple conduction blocks after TNF alpha monoclonal antibody therapy. Neurology 63(9):1754

    PubMed  Google Scholar 

  95. Jarrett SJ, Cunnane G, Conaghan PG, Bingham SJ, Buch MH, Quinn MA et al (2003) Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. J Rheumatol 30(10):2287–2291

    PubMed  Google Scholar 

  96. FDA Arthritis Advisory Committee Briefing Document (2003) Efficacy and safety review: infliximab. FDA

  97. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889–894

    Article  CAS  PubMed  Google Scholar 

  98. Khanna D, McMahon M, Furst DE (2004) Safety of tumour necrosis factor-alpha antagonists. Drug Saf 27(5):307–324

    Article  CAS  PubMed  Google Scholar 

  99. Midgard R, Grønning M, Riise T, Kvåle G, Nyland H (1996) Multiple sclerosis and chronic inflammatory diseases. A case-control study. Acta Neurol Scand 93(5):322–328

    Article  CAS  PubMed  Google Scholar 

  100. Nielsen NM, Frisch M, Rostgaard K, Wohlfahrt J, Hjalgrim H, Koch-Henriksen N et al (2008) Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 14(6):823–829

    Article  CAS  PubMed  Google Scholar 

  101. Sadovnick AD, Armstrong H, Rice GP, Bulman D, Hashimoto L, Paty DW et al (1993) A population-based study of multiple sclerosis in twins: update. Ann Neurol 33(3):281–285

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Antonio G. Tristano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tristano, A.G. Neurological adverse events associated with anti-tumor necrosis factor alpha treatment. J Neurol 257, 1421–1431 (2010). https://doi.org/10.1007/s00415-010-5591-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-010-5591-7

Keywords

Navigation